{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:47:46Z","timestamp":1740178066808,"version":"3.37.3"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsradet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6bergstiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ctro.2024.100785","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T14:26:44Z","timestamp":1713709604000},"page":"100785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Stable use of radiotherapy in lymphoma patients over time \u2013 A comprehensive national overview of radiotherapy use in Sweden with focus on older patients"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7063-467X","authenticated-orcid":false,"given":"Sara","family":"Ekberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Ekstr\u00f6m Smedby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4281-0349","authenticated-orcid":false,"given":"Tove","family":"W\u00e4sterlid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100785_b0005","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jnci\/dji290","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctro.2024.100785_b0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ctro.2024.100785_b0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0020","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ctro.2024.100785_b0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.24623","article-title":"Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy","volume":"92","author":"Glimelius","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctro.2024.100785_b0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.16232","article-title":"No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy","volume":"188","author":"Lagerlof","year":"2020","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.ctro.2024.100785_b0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.3151","article-title":"Reappraisal of the role of radiation therapy in lymphoma treatment","volume":"41","author":"Specht","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11864-015-0377-x","article-title":"Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?","volume":"17","author":"Specht","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0045","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100785_b0050","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0055","doi-asserted-by":"crossref","first-page":"7574 -","DOI":"10.1200\/JCO.2018.36.15_suppl.7574","article-title":"Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL\/GLA","volume":"36","author":"Pfreundschuh","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0060","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1200\/JCO.2012.48.0467","article-title":"Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement","volume":"31","author":"Held","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0065","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2024.100785_b0075","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0080","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctro.2024.100785_b0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital","volume":"54","author":"Bernard","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctro.2024.100785_b0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctro.2024.100785_b0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctro.2024.100785_b0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/0284186X.2015.1115124","article-title":"Trends in hematological cancer in the elderly in Denmark, 1980\u20132012","volume":"55","author":"Ocias","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctro.2024.100785_b0110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hon.2368","article-title":"Low-dose radiotherapy in diffuse large B-cell lymphoma","volume":"35","author":"Furlan","year":"2017","journal-title":"Hematol Oncol"},{"year":"2014","series-title":"Swedish Lymphoma Registry 2000\u20132012 (Regional Cancer Center South)","author":"Jerkeman","key":"10.1016\/j.ctro.2024.100785_b0115"},{"key":"10.1016\/j.ctro.2024.100785_b0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0130","doi-asserted-by":"crossref","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","article-title":"Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Vitolo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.26744","article-title":"Sex differences in lymphoma incidence and mortality by subtype: A population-based study","volume":"98","author":"Radkiewicz","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctro.2024.100785_b0140","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0145","doi-asserted-by":"crossref","first-page":"805","DOI":"10.6004\/jnccn.2020.7664","article-title":"Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care","volume":"19","author":"Ning","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctro.2024.100785_b0150","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1200\/JCO.21.02407","article-title":"Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy","volume":"40","author":"Lagerl\u00f6f","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0155","article-title":"Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma","volume":"8","author":"Wu","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100785_b0160","first-page":"15","article-title":"Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond","author":"Perrone","year":"2023","journal-title":"Cancers (basel)"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824000624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T22:06:00Z","timestamp":1724969160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824000624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"alternative-id":["S2405630824000624"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100785","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stable use of radiotherapy in lymphoma patients over time \u2013 A comprehensive national overview of radiotherapy use in Sweden with focus on older patients","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100785"}}